TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3070179
Drug: Intramuscular emulsified
Normalized name: diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular emulsified disulfiram (1 g in soybean emulsion)
Study: 25500831
Drug: Oral disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral disulfiram
Study: 16200718
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel (0.75 mg of 17 beta‐estradiol/d) + medroxyprogesterone acetate (2 mg/d) in group 4 (G4)
Study: 16544586
Drug: Traditional up-dosing
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional up-dosing scheme
Study: 12865191
Drug: Dermal HRT
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal HRT (17 beta‐oestradiol gel with oral progestogen)
Study: 28557736
Drug: Intervention schools
Normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention schools with increased opportunities for risk and challenge (e.g., rough-and-tumble play, reduced rules, added loose parts)
Study: 22339102
Drug: Acupuncture-like transcutaneous
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-like transcutaneous electrical nerve stimulation (AL-TENS) at Hegu (LI4) and Sanyinjiao (SP6) points, applied twice weekly for 8 weeks.
Study: 1590373
Drug: Lipid study
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid study (infusion of lipid emulsion to meet resting energy requirements during 84‐h oral fast)
Study: 1590373
Drug: Control study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control study (84 h fasting without lipid infusion)
Study: 2197382
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.25 mg/kg
Study: 26103129
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg daily for 8 weeks)
Study: 21953602
Drug: Acute cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute cortisol (30 mg hydrocortisone)
Study: 22883020
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with propofol
Study: 9649976
Drug: 5-day lofexidine
Normalized name: LOFEXIDINE
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day lofexidine treatment
Study: 8206771
Drug: Procedural modeling
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedural modeling video treatment
Study: 16765759
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy (target international normalised ratio of 2.0-3.0)
Study: 25211216
Drug: SAP therapy
Normalized name: Bambusa vulgaris sap extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP therapy (sensor-augmented pump therapy)
Study: 14963679
Drug: Occupational integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Occupational integrated rehabilitation program (2.5-3 hours twice a week for 15 weeks according to BAR guidelines) with annual check-ups.
Study: 18689571
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g resistant maltodextrin
Study: 20169858
Drug: Levocetirizine dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocetirizine dihydrochloride orally disintegrating tablets
Study: 21584681
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (maltodextrin solution)
Study: 20369059
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine (SVV)
Study: 19342599
Drug: Intralipid injection
Normalized name: Intralipid Injectable Product
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid injection
Study: 11140431
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 microg administered via Diskus or Diskhaler for 12 weeks
Study: 7917442
Drug: Daily alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily alcohol consumption
Study: 30922997
Drug: Budesonide orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide orodispersible tablet (BOT) 1 mg twice daily; n = 59
Study: 15104206
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate therapy
Study: 30598343
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion
Study: 11069197
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate daily (group 2)
Study: 11069197
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate daily (group 1)
Study: 6203784
Drug: Hormone determinations
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone determinations
Study: 15567810
Drug: midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 2 mg
Study: 31789723
Drug: Radioiodine ablation
Normalized name: Radioiodine
DrugBank: Iodide I-131 (DB09293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine ablation (RAI) with higher weight-based doses of I-131 (250 μCI/g thyroid tissue)
Study: 31789723
Drug: Maternal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal or neonatal TSH receptor antibodies and TSH at 3-7 days of age
Study: 19070418
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg per day
Study: 30591031
Drug: Valerian capsules
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian capsules taken 60 minutes before bedtime for one month
Study: 16816926
Drug: Ospemifene 30
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 30 mg
Study: 10516537
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg b.i.d. orally for 14 days (CL group)
Study: 10516537
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus cefuroxime 500 mg b.i.d. orally for 7 days (CLCE group)
Study: 7488598
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral acetazolamide
Study: 2661242
Drug: Conventional naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional naproxen capsules (500 mg twice daily)
Study: 6118983
Drug: Sudden cancellation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sudden cancellation of psychotropic drugs (with modifications such as combinations with sulfozine and diuretics)
Study: 30839405
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin bolus with glucose infusion (Group A; n = 20)
Study: 1800877
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of fentanyl combined with diazepam (greater than that used in Group I)
Study: 23989106
Drug: 10-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Study: 23989106
Drug: 5-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Study: 23989106
Drug: 3-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day amoxicillin (80 mg/kg/d; divided into 3 daily doses)
Study: 3555062
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 300 mg every 12 hours
Study: 3555062
Drug: Ciprofloxacin orally
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin orally after initial intravenous therapy
Study: 2686417
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin
Study: 8624384
Drug: Systemically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically active antifungals
Study: 21072892
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor for five days followed by autologous CD34(+) and CD133(+) stem cell infusion in the portal vein
Study: 15772912
Drug: Alvimopan 1
Normalized name: alvimopan 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvimopan 1 mg
Study: 2373139
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg suppository
Study: 2373139
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 5 mg oral tablets
Study: 16555564
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of contrast material alone (group A)
Study: 21029339
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics
Study: 17078309
Drug: Nicotine (NIC)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine (NIC) using a 21-mg transdermal patch
Study: 2210865
Drug: IgG-anti-LPS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG-anti-LPS therapy (more than 65 micrograms/ml)
Study: 1992998
Drug: Intravenous IgG
Normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous IgG
Study: 19501215
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg bid coadministered with ethinylestradiol/norethindrone
Study: 15070596
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for recurrent disease
Study: 29187901
Drug: First-line platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum-based doublet chemotherapy
Study: 21774826
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) given twice a day for three days
Study: 10386022
Drug: PVP-I nasal
Normalized name: PVP-I
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PVP-I nasal inhalation (1% PVP-I solution, 2 times/day for 2 weeks) without chronic respiratory complications
Study: 26310513
Drug: EPO mouthwash
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO mouthwash (50 IU/ml, 15 ml four times a day)
Study: 19567208
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in an unlicensed sequential regimen FEC100-T
Study: 9883434
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel (0.025%)
Study: 19922893
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of imatinib 400 mg
Study: 11125881
Drug: Abacavir and
Normalized name: Abacavir and Lamivudine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir and one protease inhibitor
Study: 28460259
Drug: Enoxaparin 40mg
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40mg SQ daily
Study: 28460259
Drug: Enoxaparin 60mg
Normalized name: ENOXAPARIN 60MG/0.6ML INJ
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 60mg SQ daily
Study: 12604544
Drug: 2-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day treatment with 2 g of valacyclovir twice daily for 1 day and then 1 g of valacyclovir twice daily for 1 day
Study: 3782679
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 1.5 to 4.5 mg epinephrine (10 to 30 inhalations)
Study: 3066849
Drug: Ganglioside GM1
Normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganglioside GM1 (100 mg) given daily by intramuscular injection for 28 days
Study: 20724576
Drug: Rituximab with
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab with CHOP-like chemotherapy
Study: 25824637
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (1,140 mg of EPA + 600 mg of DHA)
Study: 21854132
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (100 g twice a day/week)
Study: 16859579
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 (IL-2) at dose level 2: 8 MIU/m2 per day, every other week for 24 weeks (n = 9)
Study: 16859579
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 (IL-2) at dose level 4: 8 MIU/m2 per day, weeks 1-4, 9-12, and 17-20 (n = 10)
Study: 8694150
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate + Ranitidine 50 mg + Metoclopramide 10 mg (group RMC)
Study: 12525442
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 5 mg mifepristone per day for 120 days
Study: 8877932
Drug: Lornoxicam 4
Normalized name: lornoxicam 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 4 mg tid
Study: 7631635
Drug: Percentage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage of male patients reporting receptive oral sex
Study: 27492428
Drug: I-gel
Normalized name: Di-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel
Study: 7010854
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of metoprolol plus placebo
Study: 7010854
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of metoprolol plus 25 mg of hydrochlorothiazide
Study: 7713100
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg.day-1
Study: 26499920
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy with oral corticosteroids and immunosuppression
Study: 16412750
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone
Study: 14563968
Drug: Adjunct abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunct abciximab therapy (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1))
Study: 12842055
Drug: Nurse continence
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse continence advisor therapy
Study: 340005
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (nicoumalone) treatment
Study: 340005
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin calcium
Study: 7986280
Drug: Ethyl alcohol
Normalized name: Ethyl alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl alcohol 0.55‐0.66 g/kg
Study: 7986280
Drug: Blood alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood alcohol levels > 100 mg/100 ml
Study: 25925842
Drug: edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: edoxaban 60 mg once daily
Study: 31296251
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (50 mg/kg) and thiamine (200 mg) administered intravenously every 12 hours for 48 hours
Study: 2059298
Drug: CyA and
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA and MP (double drug treatment)
Study: 21256649
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (3 mg)
Study: 16356087
Drug: Subcuticular preincision
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcuticular preincision infiltration with 10 ml of bupivacaine (0.5%)
Study: 24401802
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with ropivacaine 0.75%, 30 ml at time 0 and isotonic saline after 45 min
Study: 24401802
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal block (ACB) with isotonic saline at time 0 and ropivacaine 0.75%, 30 ml after 45 min
Study: 9621668
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia with low dose fentanyl (8 micrograms.kg‐1)
Study: 3773799
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E therapy (300 mg/day intramuscularly for seven days)
Study: 11490039
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic
Study: 17938165
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine
Study: 28213595
Drug: Short Cycle
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short Cycle Therapy (SCT) (5 days on: 2 days off)
Study: 28213595
Drug: Continuous efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous efavirenz (EFV)-based antiretroviral therapy (CT)
Study: 7604684
Drug: Maternal antiphospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antiphospholipid antibodies (aPA) measured by anticardiolipin antibodies (aCL)
Study: 2662354
Drug: Praziquantel 45
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel 45 mg daily dose
Study: 3086359
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 200 mg im every 2 weeks
Study: 3086359
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 100 mg im once a week
Study: 1621434
Drug: IgM-anticardiolipin-antibodies in
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-anticardiolipin-antibodies in all groups
Study: 20484099
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg before the intervention and 200 mg twice daily for 6 months)
Study: 16454155
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (Aclasta®), 5 mg infusion
Study: 21315223
Drug: VerifyNow Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VerifyNow Aspirin Assay (Accumetrics), MEA ASPI test, MEA ADP test
Study: 11475717
Drug: Weishu capsule
Normalized name: BENZODODECINIUM BROMIDE 0.3948 g in 420 mL / METHENAMINE 1.092 g in 420 mL EXTRACORPOREAL LIQUID [Youjie Weishi Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weishu capsule (WSC)
Study: 16029524
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment
Study: 15701213
Drug: Desloratadine syrup
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine syrup 1.25 mg (0.5 mg/mL) once daily for ages 2-5 years
Study: 15701213
Drug: Desloratadine syrup
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine syrup 2.5 mg once daily for ages 6-11 years
Study: 1557934
Drug: SPf66 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPf66 vaccine
Study: 12208571
Drug: Pilocarpine 5
Normalized name: PILOCARPINE 5MG/UNT OPH,CRC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5 mg three times daily
Study: 24161333
Drug: AMG 145
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 145 (PCSK9 monoclonal antibody)